

# Synthesis and pharmacology of halogenated $\delta$ -opioid selective [ $DAla^2$ ] Deltorphin II peptide analogs





*Robyn Pescatore<sup>c+</sup>, Gina F. Marrone<sup>a,b+</sup>, Seth Sedberry<sup>c</sup>, Daniel Vinton<sup>c</sup>, Netanel Finkelstein<sup>b</sup>, Yitzchak E. Katlowitz<sup>b</sup>, Gavril W. Pasternak<sup>a,b</sup>, Krista R. Wilson<sup>c\*</sup> and Susruta Majumdar<sup>b\*</sup>*

<sup>a</sup>Department of Neuroscience, Weil Cornell Medical College, 1300 York Avenue, NY, NY 10065

<sup>b</sup>Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, NY, NY 10065

<sup>c</sup>Department of Chemistry, Wingate University, PO Box 159, Wingate, NC 28174

Supplementary Figure 1.



A) UV of HPLC of **3** confirming retention time of desired product.

B) UV of HPLC of  $^{125}$ I iodination of **5** to produce [ $^{125}$ I]-**3**.

- C) Radiometric detection of  $^{125}\text{I}$  iodination of **5** to produce [ $^{125}\text{I}$ ]-**3** from same run presented in B.
- D) Radiometric detection of purified [ $^{125}\text{I}$ ]-**3**.